Navigation Links
BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
Date:1/6/2012

cipate in the call which can be accessed at www.bdsi.com or toll-free at (866) 516-3002 or at (760) 298-5082.  For those who are not able to listen to the live broadcast, a replay of the call will be made available on the BDSI website.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence.  BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo Pharmaceuticals.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioDelivery Sciences Announces Confirmation of Final Formulation of BEMA Buprenorphine/Naloxone Based on Positive BNX-102 Study
2. BioDelivery Sciences to Host Business Update Webcast and Conference Call on Tuesday, November 15, 2011 at 8:30 AM Eastern Time
3. BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
4. Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors
5. BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
6. BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
7. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
8. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
9. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
10. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
11. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Confirms Effectiveness of Autologous Therapy, DUSSELDORF, ... a two-year,representative study of knee osteoarthritis, published ... confirm,the safety and effectiveness of Orthokine therapy, ... own blood are,injected into the arthritic joint., ...
... Phase III Study to Explore the Effects of ... Calcitonin on Vertebral Fractures in Postmenopausal Women, ... (Nasdaq: EMIS ) announced today that Novartis ... III study exploring the,safety and efficacy of Salmon ...
Cached Medicine Technology:Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years 2Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment 2
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ) as,its ... announced transaction,between Takeda Pharmaceutical Company Limited and Alnylam. ... of future milestone and royalty,payments. This transaction further ...
... of almonds closer to that of roses or bananas? Weizmann ... for the first time that smells can be mapped and ... appeared recently in Nature Methods, may help scientists to unravel ... as potentially enabling odors to be digitized and transferred via ...
... Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) (,Lotus, or the ... China ("PRC"), today,announced that it will conduct a ... May 27, 2008 to discuss the first quarter ... and Chief Executive Officer of Lotus,Pharmaceuticals, will be ...
... ON, May 27 /PRNewswire-FirstCall/ - AlphaRx (OTC ... proprietary drug,delivery technology to develop novel formulations ... and USAMRIID (U.S. Army Medical Research Institute ... Research and,Development Agreement for Material Transfer (MTA). ...
... UCLA have identified a type of leukemia stem cell and ... blood stem cells to become cancerous. , The discovery may ... attacking the disease at its very root and killing the ... The study appears in the May 22, 2008 issue of ...
... Dozens of Videos from Doctors and Students at Seattle Children,s Hospital, Swedish ... ... Available,Videos Offer Insight and Advice on Topics Ranging from Pediatrics to Cancer ... Screening to Novel Surgical Techniques, NEW YORK, May 27 ...
Cached Medicine News:Health News:Isis to Receive $4.6 Million From Alnylam 2Health News:Isis to Receive $4.6 Million From Alnylam 3Health News:Weizmann Institute scientists produce the first smell map 2Health News:Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 3Health News:AlphaRx Signs Cooperative Research and Development Agreement with US Army 2Health News:UCLA researchers identify leukemia stem cells 2Health News:The Doctor's Channel Launches New Videos from Three Top Hospitals 2Health News:The Doctor's Channel Launches New Videos from Three Top Hospitals 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: